471 related articles for article (PubMed ID: 35395355)
1. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
[TBL] [Abstract][Full Text] [Related]
2. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
3. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
[TBL] [Abstract][Full Text] [Related]
4. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
5. Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
McMahon DJ; Gleeson JP; O'Reilly S; Bambury RM
Med Oncol; 2022 Jun; 39(9):129. PubMed ID: 35716200
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W; Klockow JL; Zhang M; Lafortune F; Chang E; Jin L; Wu Y; Daldrup-Link HE
Pharmacol Res; 2021 Sep; 171():105780. PubMed ID: 34302977
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
9. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
Liang R; Wu C; Liu S; Zhao W
Drug Deliv; 2022 Dec; 29(1):1620-1630. PubMed ID: 35612318
[TBL] [Abstract][Full Text] [Related]
10. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies for improving the prognosis of glioblastoma.
Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
[No Abstract] [Full Text] [Related]
12. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
13. A narrative review of research progress on drug therapies for glioblastoma multiforme.
Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
[TBL] [Abstract][Full Text] [Related]
14. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
[TBL] [Abstract][Full Text] [Related]
15. Immune check-point in glioblastoma multiforme.
De Felice F; Pranno N; Marampon F; Musio D; Salducci M; Polimeni A; Tombolini V
Crit Rev Oncol Hematol; 2019 Jun; 138():60-69. PubMed ID: 31092387
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
17. Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities.
Gupta T; Sahoo RK; Singh H; Katke S; Chaurasiya A; Gupta U
AAPS PharmSciTech; 2023 Apr; 24(4):102. PubMed ID: 37041350
[TBL] [Abstract][Full Text] [Related]
18. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
[TBL] [Abstract][Full Text] [Related]
19. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Multiforme-A Look at the Past and a Glance at the Future.
King JL; Benhabbour SR
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
